Humans ; Neck ; pathology ; Neoplasms, Second Primary ; diagnosis ; Neurilemmoma ; diagnosis

Aged ; Female ; Humans ; Neoplasms, Multiple Primary ; pathology ; physiopathology ; Neoplasms, Second Primary ; pathology ; physiopathology

Humans ; Neuroendocrine Tumors/pathology* ; Pancreatic Neoplasms/pathology* ; Neoplasms, Second Primary ; von Hippel-Lindau Disease/pathology*

Currently, surgery-based comprehensive therapy plays an important role in the treatment of local advanced gastric cancer (LAGC), and standard lymph node dissection is a mainstay of gastric surgery. Radical gastrectomy with D2 lymph node dissection is widely accepted based on the international publications of randomized clinical trials, but the extent of lymph node dissection is controversial. An adequate lymph node dissection may improve prognosis and reduce complications, and D2+ lymphadenectomy may improve surgical outcomes in some selected patients. To improve the efficacy of LAGC therapies, the Gastric Cancer Association, China Anti Cancer Association took the lead and organized experts to discuss and vote, and finally formulated this expert consensus. It is hoped that this consensus can provide reference for clinicians and further improve the diagnosis and treatment level of LAGC in China.
Consensus ; Gastrectomy ; Humans ; Lymph Node Excision ; Neoplasms, Second Primary/surgery* ; Prognosis ; Stomach Neoplasms/pathology*

Breast cancer and lung cancer are the two most common malignancies in China. With the continuous improvement of breast cancer diagnosis and treatment technology, the survival time of breast cancer patients has been prolonged, and the number of breast cancer patients with second primary lung cancer (SPLC) has increased. In addition, breast cancer is the most common primary cancer in female patients with SPLC, and SPLC is the main cause of death in this population. More and more physicians pay attention to this clinical phenomenon. This paper summarized the risk and risk factors of SPLC in breast cancer patients, and elaborated its pathogenesis, in order to provide a theoretical basis for the clinical management of breast cancer patients and achieve accurate early intervention as soon as possible.
.
Humans ; Female ; Lung Neoplasms/pathology* ; Carcinoma, Non-Small-Cell Lung/pathology* ; Breast Neoplasms/complications* ; Neoplasms, Second Primary/pathology* ; Risk Factors

INTRODUCTIONMetastatic disease to the liver in colorectal cancer is a common entity that may present synchronously or metachronously. While increasing surgical experience has improved survival outcomes, some evidence suggest that synchronous lesions should be managed differently. This review aims to update current literature on differences between the outcomes and management of synchronous and metachronous disease.

MATERIALS AND METHODSSystematic review of MEDLINE database up till November 2008.

RESULTSDiscrete differences in tumour biology have been identified in separate studies. Twenty-one articles comparing outcomes were reviewed. Definitions of metachronicity varied from anytime after primary tumour evaluation to 1 year after surgery for primary tumour. Most studies reported that synchronous lesions were associated with poorer survival rates (8% to 16% reduction over 5 years). Sixteen articles comparing combined vs staged resections for synchronous tumour showed comparable morbidity and mortality. Benefits over staged resections included shorter hospital stays and earlier initiation of chemotherapy. Suitability for combined resection depended on patient age and constitution, primary tumour characteristics, size and the number of liver metastases, and the extent of liver involvement.

CONCLUSIONSSurgery remains the only treatment option that offers a chance of long-term survival for patients amenable to curative resection. Synchronicity suggests more aggressive disease although a unifying theory for biological differences explaining the disparity in tumour behaviour has not been found. Combined resection of primary tumour and synchronous metastases is a viable option pending careful patient selection and institutional experience. Given the current evidence, management of synchronous and metachronous colorectal liver metastases needs to be individualised to the needs of each patient.

Biomarkers, Tumor ; Colorectal Neoplasms ; mortality ; pathology ; surgery ; Humans ; Liver Neoplasms ; mortality ; secondary ; surgery ; Neoplasms, Multiple Primary ; mortality ; pathology ; surgery ; Neoplasms, Second Primary ; mortality ; pathology ; surgery ; Prognosis

BACKGROUND: Previous studies have revealed that the number of cancer survivors developing a second primary malignancy is increasing, especially among thyroid cancer patients, and lung cancer is still the main cause of cancer death. Therefore, we aimed to investigate the risk of second primary lung cancer (SPLC) in patients with thyroid cancer. METHODS: We searched the PubMed, Web of Science, Embase, and Scopus databases up to November 24, 2021, for relevant research and merged the standardized incidence ratios (SIRs) and 95% confidence intervals (95% CIs) to evaluate the risk of developing SPLC in patients with thyroid cancer. RESULTS: Fourteen studies involving 1,480,816 cases were included in our meta-analysis. The pooled result demonstrated that thyroid cancer patients may have a higher risk of SPLC than the general population (SIR = 1.21, 95% CI: 1.07-1.36, P  < 0.01, I2  = 81%, P  < 0.01). Subgroup analysis stratified by sex indicated that female patients may have a markedly higher risk of SPLC than male patients (SIR = 1.65, 95% CI: 1.40-1.94, P  < 0.01, I2  = 75%, P  < 0.01). CONCLUSIONS: Thyroid cancer patients are more likely to develop SPLC than the general population, especially women. However, other risk factors must be investigated, and more prospective studies are needed to confirm our results. REGISTRATION International Prospective Register of Systematic Reviews: No. CRD42021285399.
Humans ; Male ; Female ; Neoplasms, Second Primary/pathology* ; Systematic Reviews as Topic ; Lung Neoplasms/pathology* ; Risk Factors ; Thyroid Neoplasms/complications* ; Incidence

We wanted to present the results of our experience with bilateral testis tumor and to suggest the effects of chemotherapy in suppressing the development of second primary testicular tumors. Between 1978 and 1997, 2,345 patients were treated for testicular tumor at The University of Texas M. D. Anderson Cancer Center. Of these, 2,107 had germ cell cancers. There were 22 (0.94%) cases of bilateral testicular tumor in the overall patient population and 21 (1.0%) cases among patients with germ cell cancer. We reviewed the medical records to determine the incidence of the histological subtype, the incidence of metachronous versus synchronous formation of contralateral tumors, and tumor stage in this patient population. We also examined the effect of chemotherapy in treating the first tumor and preventing the occurrence of a second tumor. Finally, we compared the effect of ultrasonography, serum tumor marker elevation, and physical examination in detecting second tumors. Only one contralateral germ cell tumor developed synchronously; all others developed metachronously. Fifty percent of first tumors were seminomas, compared to 55% of second tumors. The histologic concordance rate for first and second tumors was 35%. Tumor stage was higher among first tumors than second tumors. The majority of second tumors in patients who received chemotherapy for first malignancies tended to be metachronous seminomas. Ultrasonography detected 6 of 21 (28.6%) contralateral tumors before they were evident by physical examination or serum tumor marker elevation. Seminomas were more prevalent among patients with bilateral germ cell disease than patients with unilateral disease. Chemotherapy, when used as treatment for first tumors, may have some effect in preventing the development of nonseminomatous germ cell tumors in the contralateral testicle. Close follow-up of the contralateral testis with ultrasonography is essential for early detection of second tumors. The outcome for patients with bilateral testicular germ cell cancer is excellent, secondary to early detection.
Adolescence ; Adult ; Antineoplastic Agents/therapeutic use* ; Human ; Incidence ; Male ; Neoplasms, Multiple Primary/epidemiology ; Neoplasms, Second Primary/prevention & control* ; Neoplasms, Second Primary/epidemiology ; Testicular Neoplasms/pathology ; Testicular Neoplasms/drug therapy*

Gastrectomy is known to be a risk factor for adenocarcinoma in remnant stomach. It is suggested that reflux of bile juice or duodenal secretion to remnant stomach induces atrophic gastritis, intestinal metaplasia, and gastric adenocarcinoma. Malignant lymphoma in remnant stomach after gastrectomy is very rare. Only about thirty cases are reported in the world, and there is no case report in Korea. Gastric MALT (mucosa-associated lymphoid tissue) lymphoma is associated with Helicobacter pylori infection but the mechanism of lymphoma development in remnant stomach is still unknown. We report a case of low grade gastric MALT lymphoma of gastric stump after 10 years from partial gastrectomy.
Aged ; *Gastrectomy ; *Gastric Stump ; Humans ; *Lymphoma, B-Cell, Marginal Zone/pathology ; Male ; *Neoplasms, Second Primary ; Stomach Neoplasms/pathology/*surgery

The application of pelviscopic surgery for the management of ovarian tumors has increased dramatically in the last few years. Of particular concern is the pelviscopic excision of malignant ovarian tumors. One of the important potential problems with this approach is disseminating malignant cells to peritoneal surface. The aim of this report is to draw attention to the possibility of the occurrence of a tumor implantation at the pelviscopic port site in patients with malignant ovarian tumors. A case is presented here in which a localized tumor implant occurred in the abdominal trocar site after pelviscopic removal of ovarian mass subsequently found to be squamous cell carcinoma arising in mature cystic teratoma with brief review of literatures.
Abdomen ; Adult ; Carcinoma, Squamous Cell/*pathology/surgery ; Case Report ; Female ; Human ; *Neoplasms, Second Primary ; Ovarian Neoplasms/*pathology/surgery ; Pelvis